Cargando…

Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★

In this historical cohort study, 236 patients with primary rheumatoid arthritis were treated with the tumor necrosis factor inhibitors, etanercept or infliximab (n = 80), or by conventional methods (n = 156). Results revealed that 11 patients developed varying types of peripheral neuropathy at 1–2 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Naizhi, Guo, Yingying, Yang, Lili, Fu, Wenyi, Xu, Yanbing, Hou, Linxin, Zhao, Shuai, Zhang, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342715/
https://www.ncbi.nlm.nih.gov/pubmed/25737715
http://dx.doi.org/10.3969/j.issn.1673-5374.2012.11.011
_version_ 1782359309174177792
author Wang, Naizhi
Guo, Yingying
Yang, Lili
Fu, Wenyi
Xu, Yanbing
Hou, Linxin
Zhao, Shuai
Zhang, Ning
author_facet Wang, Naizhi
Guo, Yingying
Yang, Lili
Fu, Wenyi
Xu, Yanbing
Hou, Linxin
Zhao, Shuai
Zhang, Ning
author_sort Wang, Naizhi
collection PubMed
description In this historical cohort study, 236 patients with primary rheumatoid arthritis were treated with the tumor necrosis factor inhibitors, etanercept or infliximab (n = 80), or by conventional methods (n = 156). Results revealed that 11 patients developed varying types of peripheral neuropathy at 1–2 years post-treatment (mean 16 months). The incidence of peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 8.8% (7/80), which was significantly higher than the conventional treatment group (2.6%; 4/156). The relative risk of developing peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 3.41 (95% confidence interval: 1.03–11.31). Comparison of the tumor necrosis factor inhibitors revealed that etanercept and infliximab had no significant difference in terms of inducing peripheral neuropathy. Experimental findings indicate that tumor necrosis factor inhibitors may increase the risk of peripheral neuropathy.
format Online
Article
Text
id pubmed-4342715
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-43427152015-03-03 Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★ Wang, Naizhi Guo, Yingying Yang, Lili Fu, Wenyi Xu, Yanbing Hou, Linxin Zhao, Shuai Zhang, Ning Neural Regen Res Clinical Practice In this historical cohort study, 236 patients with primary rheumatoid arthritis were treated with the tumor necrosis factor inhibitors, etanercept or infliximab (n = 80), or by conventional methods (n = 156). Results revealed that 11 patients developed varying types of peripheral neuropathy at 1–2 years post-treatment (mean 16 months). The incidence of peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 8.8% (7/80), which was significantly higher than the conventional treatment group (2.6%; 4/156). The relative risk of developing peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 3.41 (95% confidence interval: 1.03–11.31). Comparison of the tumor necrosis factor inhibitors revealed that etanercept and infliximab had no significant difference in terms of inducing peripheral neuropathy. Experimental findings indicate that tumor necrosis factor inhibitors may increase the risk of peripheral neuropathy. Medknow Publications & Media Pvt Ltd 2012-04-15 /pmc/articles/PMC4342715/ /pubmed/25737715 http://dx.doi.org/10.3969/j.issn.1673-5374.2012.11.011 Text en Copyright: © Neural Regeneration Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Practice
Wang, Naizhi
Guo, Yingying
Yang, Lili
Fu, Wenyi
Xu, Yanbing
Hou, Linxin
Zhao, Shuai
Zhang, Ning
Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★
title Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★
title_full Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★
title_fullStr Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★
title_full_unstemmed Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★
title_short Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study★
title_sort effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: a cohort study★
topic Clinical Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342715/
https://www.ncbi.nlm.nih.gov/pubmed/25737715
http://dx.doi.org/10.3969/j.issn.1673-5374.2012.11.011
work_keys_str_mv AT wangnaizhi effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy
AT guoyingying effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy
AT yanglili effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy
AT fuwenyi effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy
AT xuyanbing effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy
AT houlinxin effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy
AT zhaoshuai effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy
AT zhangning effectoftumornecrosisfactorinhibitorsonrheumatoidarthritisinducedperipheralneuropathyacohortstudy